Bispecific antigen-binding constructs targeting Her2

Patent metadata

Field	Value
Publication number	US-11325981-B2
Application number	US-201816011048-A
Country	US
Kind code	B2
Filing date	Jun 18, 2018
Priority date	Nov 27, 2013
Publication date	May 10, 2022
Grant date	May 10, 2022

Abstract

Provided herein are biparatopic antigen-binding constructs that specifically bind HER2. The biparatopic antigen-binding constructs comprise one antigen-binding moiety that binds to ECD2 of HER2, a second antigen-binding moiety that binds to ECD4 of HER2, and an Fc. At least one of the antigen-binding moieties is an scFv. The biparatopic antigen-binding constructs can be used in the treatment of cancer.

First claim

The invention claimed is:

1. An isolated antigen binding construct comprising
a first antigen-binding polypeptide construct which specifically binds a HER2 (human epidermal growth factor receptor 2) ECD2 (extracellular domain 2) antigen on a HER2-expressing cell, wherein the first antigen binding polypeptide construct comprises a first heavy chain variable region (VH1) and a first light chain variable region (VL1), wherein the VH1 comprises a CDR1 comprising the sequence shown in SEQ ID NO:348, a CDR2 comprising the sequence shown in SEQ ID NO:335, and a CDR3 comprising the sequence shown in SEQ ID NO:336, and the VL1 comprises a CDR1 comprising the sequence shown in SEQ ID NO:340, a CDR2 comprising the sequence shown in SEQ ID NO:338, and a CDR3 comprising the sequence shown in SEQ ID NO:347,
wherein the first antigen-binding polypeptide construct comprises a first heavy chain H1 comprising the VH1 and a first light chain L1 comprising the VL1, and the first H1 comprises the sequence shown in SEQ ID NO:97 and the first L1 comprises the sequence shown in SEQ ID NO:69.

2. The isolated construct of claim 1 , wherein the first antigen binding polypeptide construct is a Fab.

3. The isolated construct of claim 1 , wherein the first H1 consists of the sequence shown in SEQ ID NO:97 and the first L1 consists of the sequence shown in SEQ ID NO:69.

4. The isolated construct of claim 1 , further comprising a second antigen binding polypeptide construct operably linked to the first antigen binding polypeptide construct, wherein the second antigen binding polypeptide construct comprises a second heavy chain variable domain (VH2) and a second light chain variable domain (VL2).

5. The isolated construct of claim 4 , wherein the VH2 comprises a CDR1 comprising the sequence shown in SEQ ID NO:343, a CDR2 comprising the sequence shown in SEQ ID NO:341, and a CDR3 comprising the sequence shown in SEQ ID NO:342, and the VL2 comprises a CDR1 comprising the sequence shown in SEQ ID NO:346, a CDR2 comprising the sequence shown in SEQ ID NO:344, and a CDR3 comprising the sequence shown in SEQ ID NO:345.

6. The isolated construct of claim 4 , wherein the first antigen polypeptide construct is a Fab and the second antigen polypeptide construct is an scFv.

7. The isolated construct of claim 5 , wherein the first antigen polypeptide construct is a Fab and the second antigen polypeptide construct is an scFv.

8. The isolated construct of claim 5 , wherein the first antigen binding polypeptide construct is a Fab and the VH1 comprises the sequence shown in SEQ ID NO:99 and the VL1 comprises the sequence shown in SEQ ID NO:71.

9. The isolated construct of claim 5 , wherein the first antigen binding polypeptide construct is a Fab and the VH1 comprises the sequence shown in SEQ ID NO:99 and the VL1 comprises the sequence shown in SEQ ID NO:71; and the second antigen binding polypeptide construct is an scFv and the VH2 comprises the sequence shown in SEQ ID NO:297 and the VL2 comprises the sequence shown in SEQ ID NO:305.

10. The isolated construct of claim 5 , wherein the first antigen binding polypeptide construct comprises a first heavy chain (H1) comprising the VH1 and a first light chain (L1) comprising the VL1, and the H1 consists of the sequence shown in SEQ ID NO:97 and the L1 consists of the sequence shown in SEQ ID NO:69; and the second antigen binding polypeptide construct consists of the sequence shown in SEQ ID NO:295.

11. The isolated construct of claim 1 , further comprising a heterodimeric Fc comprising a first Fc polypeptide and a second Fc polypeptide, the first Fc polypeptide comprising a first CH3 sequence and the second Fc polypeptide comprising a second CH3 sequence, wherein the first Fc polypeptide is operably linked to the first antigen-binding polypeptide construct.

12. The isolated construct of claim 11 , wherein the heterodimeric Fc is a human IgG1 Fc, the first Fc polypeptide is operably linked to the first antigen binding polypeptide construct with an IgG1 hinge region linker, the first CH3 sequence comprises T350V_L351Y_F405A_Y407V in the first Fc polypeptide, and the second CH3 sequence comprises T350V_T366L_K392L_T394W according to EU numbering compared to a wild-type homodimeric human IgG1 Fc.

13. The isolated construct of claim 5 , further comprising a heterodimeric Fc comprising a first Fc polypeptide and a second Fc polypeptide, the first Fc polypeptide comprising a first CH3 sequence and the second Fc polypeptide comprising a second CH3 sequence, wherein the first Fc polypeptide is operably linked to the first antigen-binding polypeptide construct and the second Fc polypeptide is operably linked to the second antigen-binding polypeptide construct.

14. The isolated construct of claim 13 , wherein the heterodimeric Fc is a human IgG1 Fc, the first Fc polypeptide is operably linked to the first antigen binding polypeptide construct with an IgG1 hinge region linker, the first CH3 sequence comprises T350V_L351Y_F405A_Y407V modifications in the first Fc polypeptide, and the second CH3 sequence comprises T350V_T366L_K392L_T394W modifications according to EU numbering compared to a wild-type homodimeric human IgG1 Fc.

15. The isolated construct of claim 13 , wherein the heterodimeric Fc is a human IgG1 Fc, the first Fc polypeptide is operably linked to the first antigen binding polypeptide construct with an IgG1 hinge region linker, the first CH3 sequence comprises T350V_L351Y_F405A_Y407V modifications in the first Fc polypeptide, the second Fc polypeptide is operably linked to the second antigen binding polypeptide construct with an IgG1 hinge region linker, and the second CH3 sequence comprises T350V_T366L_K392L_T394W modifications according to EU numbering compared to a wild-type homodimeric human IgG1 Fc.

16. The isolated construct of claim 11 , wherein the heterodimeric Fc comprises one or more CH2 modifications.

17. The isolated construct of claim 1 , wherein the isolated construct is glycosylated.

18. The isolated construct of claim 1 , wherein the isolated construct is conjugated to a drug.

19. A pharmaceutical composition comprising the isolated construct of claim 1 and a pharmaceutical carrier.

Assignees

• Zymeworks Inc

Inventors

• Weisser Nina E
• Ng Gordon Yiu Kon
• Wickman Grant Raymond
• Dixit Surjit Bhimarao
• Escobar-Cabrera Eric
• Sanches Mario

Classifications

• G01N33/5759

  involving compounds localised on the membrane of tumour or cancer cells · CPC title

• A61P35/00

  Antineoplastic agents · CPC title

• A61K47/6803

  Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates · CPC title

• C07K2317/622

  Single chain antibody (scFv) · CPC title

• C07K2317/732

  Antibody-dependent cellular cytotoxicity [ADCC] · CPC title